Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy - Wikidata - wikimedia - TriplyDB

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy

http://www.wikidata.org/entity/Q33692709

about

Practical approach to the patient with hypereosinophilia Current Diagnostic and Therapeutic Aspects of Eosinophilic Myocarditis Eosinophilic Granulomatosis With Polyangiitis With Thrombotic Microangiopathy: Is Simultaneous Systemic Lupus Erythematosus Associated With Clinical Manifestations?: A Case Report and Review of the Literature Novel Therapies for Eosinophilic Disorders Eosinophilia in Hematologic Disorders Spectrum of Eosinophilic End-Organ Manifestations Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field A case of idiopathic hypereosinophilic syndrome presenting with acute respiratory distress syndrome Two cases of acute myelitis with idiopathic hypereosinophilic syndrome.Eosinophilia in mast cell disease Eosinophilic myeloproliferative disorders What targeting eosinophils has taught us about their role in diseases.Eosinophilic gastroenteritis and related eosinophilic disorders Hypereosinophilic syndrome and hemimelia in a patient with chromosome 6p22.3 deletion.Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.Hypereosinophilic Syndrome.Analysing the eosinophil cationic protein--a clue to the function of the eosinophil granulocyte.IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series.Eosinophils: changing perspectives in health and disease.Biologic therapies targeting eosinophils: current status and future prospects.Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody.A Hypereosinophilic Syndrome with Cardiac Involvement from Thrombotic Stage to Fibrotic Stage.Therapeutic approaches to patients with hypereosinophilic syndromes.How I treat hypereosinophilic syndromes.The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases Refining the definition of hypereosinophilic syndrome.Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8 Reversible Severe Eosinophilic Endomyocardial Fibrosis During Pregnancy: A Case Report Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD).NIK prevents the development of hypereosinophilic syndrome-like disease in mice independent of IKKα activation Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.Rapidly evolving asymptomatic eosinophilia in a patient with lung adenocarcinoma causes cognitive disturbance and respiratory insufficiency: Case report.Eosinophilic cystitis presented as a manifestation of hypereosinophilic syndrome: a case report and review of the literature Novel targeted therapies for eosinophilic disorders A Case of Erythroderma Secondary to Hypereosinophilia.Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review.Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.Rapid Change in Mental Status in a Patient with Hypereosinophilia.

P2860

Q24610994-036196FE-1DF3-49D9-8C14-2F9C82C393C6 Q26765206-0AE3781D-A003-4DD9-B3F2-1E18C78B12ED Q26777537-BA06FABB-9675-4ED1-954C-86300CA1C6AD Q26799600-2F0EF78A-ACAE-43FB-9A1C-1BA94F37F14B Q26799611-543DDC20-F78D-440E-8E13-E5139E345E2E Q26799618-81D4D094-A12E-484E-9451-99A0FD736915 Q27003331-8BC26099-DBA9-44EC-86CA-71A702366AB5 Q33412564-0CB56513-D65F-4E10-A864-E25FE42D5643 Q33691801-FE3961D4-56D9-4F57-A590-7C2217B8813F Q33851724-35EBD177-E699-4FD4-AEC5-A9B549D60364 Q33881283-B3D0D3B5-F9BF-4455-8C2C-574881135B6F Q33987218-E46CEE7D-DCF8-4467-A89C-C9B4B00E77EB Q34035270-2FAF6849-7FDE-45AE-84CF-6A1682C097FC Q34111787-6D0833B9-6DF2-4CE7-8CD7-00CBF677B4C6 Q34176798-8B4557BB-A670-4B35-BD5A-FC4ED4CB5EC3 Q34447936-4500B30A-25FD-4635-B21D-05C74CA195F6 Q34495630-CDD2181C-A772-4A6A-96CE-EBF85FD3E534 Q34498306-A4FD9532-A183-4C3E-85CB-BD839B20B12D Q34537757-BD289534-F75D-4313-B89B-869971F4F41C Q34547831-66487480-79CB-40EC-908F-75A103297FB1 Q35170969-454F3B03-D583-4F45-BACB-6B6D1AE629A3 Q35565533-3A20803C-97CF-4D6D-A625-386725A41137 Q35652636-48C1FEC5-538E-4B69-B2F1-BB503AD98D24 Q35800672-C9EF0E3F-5083-466B-8787-2E9B725F0389 Q35857340-ADA633A8-620B-446B-A661-E0606BA253D5 Q36000858-B67CE78B-87F5-43BF-83E2-9CA926EA959E Q36008991-881D63D7-3ACC-4536-8A7E-B9E732BC93C7 Q36103687-056AEF7B-B23A-4854-A06A-40F247CE0160 Q36139731-31DDB52F-5B2C-4311-A876-6691B3D8BD3C Q36195067-A2F75FDB-EDE3-44E7-B99F-255E3A81C22D Q36206063-6A5207A0-5D07-4E21-A467-978DD31E157D Q36493668-B1247742-BC79-4748-BF01-63326044AEF9 Q36573038-3EBD01A9-A338-40F0-A4AE-A86F97322EDC Q36611808-EDA600F1-0894-4F32-AEFF-4315B03E734B Q36744360-8DA7C3D5-6CB3-4902-9140-B920255C753E Q36763565-77453463-4C89-4952-96DB-94D62F099FE4 Q37102781-1808AEC6-B857-4FFD-98EA-1ABEC4C42185 Q37226282-EB2053E3-BDD5-4BB7-A2A8-04EA619D7010 Q37362888-E0D32790-38C6-41DA-80F8-E0D187C4AB26 Q37601849-14B98A4D-1EF9-4174-BC37-366342AF6021

P2860

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy

http://www.wikidata.org/entity/Q33692709

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Hypereosinophilic syndrome: a ...... istics and response to therapy

@ast

Hypereosinophilic syndrome: a ...... istics and response to therapy

@en

type

label

Hypereosinophilic syndrome: a ...... istics and response to therapy

@ast

Hypereosinophilic syndrome: a ...... istics and response to therapy

@en

prefLabel

Hypereosinophilic syndrome: a ...... istics and response to therapy

@ast

Hypereosinophilic syndrome: a ...... istics and response to therapy

@en

P1433

Q33692709-06FC1BB0-8A5A-4414-9AEC-5631CDF4B319

P1476

Q33692709-43CF600A-8A31-478B-8C6F-BF6CCA239F6B

P2093

Q33692709-0815AFA1-8195-4C24-8C5A-A634B64C1CA5

Q33692709-1F3B5845-E288-4B89-98EE-56AE40CC0130

Q33692709-280DD01D-73ED-4C3F-BE5C-474380CFDD8C

Q33692709-419E624E-2ED7-4279-BC25-924C102047AC

Q33692709-42626B1A-513D-41EB-A273-357F29050F95

Q33692709-46E648EF-F688-40D3-B2AC-C3874221175A

Q33692709-7EF6F482-C5F3-4558-93FC-F97375416DF8

Q33692709-815678A8-D1A3-49C9-807F-DF121EEA6C0A

Q33692709-860131AB-5E7C-4202-87BB-4A485F3EAA4F

Q33692709-8C90E79B-3766-4CEB-8DE5-89BE121C2D33

P2860

Q33692709-12DD1FDB-7972-468D-9B29-7DF8BE5EB8FC

Q33692709-43208977-87C0-4495-86BB-A7567C02B146

Q33692709-4EB57F42-A3E7-4973-9F87-D1BAE5907D75

Q33692709-70523576-BEC7-4874-8FE8-2B6621AF7115

Q33692709-9A6A5A30-E6EF-41A9-9039-441A8512D67E

Q33692709-A11F847A-382C-4269-8E8E-4C539F353D32

Q33692709-A278B035-EDBD-496E-A3C5-F24358F1440D

Q33692709-BD25BAE3-4BCF-4C6B-8D83-065D94824CC3

Q33692709-C2FD7A01-5841-4FAC-8D33-D5AF34D634E7

Q33692709-E36185C1-4D9F-41FC-99B7-A385413D3CE7

P304

Q33692709-58EFE402-2D18-4B33-997A-4C539A030862

P31

Q33692709-069BA805-B6FB-4E54-9020-1AFFD1E72C60

P356

Q33692709-B0664013-BB60-4680-AB9A-5279A11DC9B2

P407

Q33692709-CE8C5B28-7765-49EE-AC2F-623451F0E410

P433

Q33692709-E3DAC98F-BEC4-4BF8-A7AE-BCD3F6C5E2F1

P478

Q33692709-A8A041C1-F5FA-4C85-A95B-2BAF5C8BF4AE

P50

Q33692709-30914422-A4ED-480A-AB1A-DE9790191C12

Q33692709-A2FF2F38-FB5C-40D0-9AEE-FE820D8425F0

Q33692709-AD635177-4BAB-4F2F-AA17-ED0F1B374148

Q33692709-DB0B4F00-C60B-484C-92DF-73F67926678D

Q33692709-E8FB1EA0-62B6-4EB1-B2D5-D24E0825C253

P577

Q33692709-1035DB9A-783B-42CF-96D9-7302A2133C6E

P5875

Q33692709-E69F3AA1-49FD-41C7-AA4D-8002175ADC34

P698

Q33692709-030A253B-E86F-4573-A916-EDB2794B1216

P921

Q33692709-B0552BCF-AC3E-45F7-99A6-2590C0D12D75

P932

Q33692709-18F849BD-3F59-46AA-B175-98E15A8F3470

P356

J.JACI.2009.09.022

P1433

The Journal of Allergy and Clinical Immunology

P1476

Hypereosinophilic syndrome: a ...... istics and response to therapy

@en

P2093

Bruce S Bochner

http://www.w3.org/2001/XMLSchema#string

Dagmar Simon

http://www.w3.org/2001/XMLSchema#string

Florence Roufosse

http://www.w3.org/2001/XMLSchema#string

Florian Pfab

http://www.w3.org/2001/XMLSchema#string

Gerald J Gleich

http://www.w3.org/2001/XMLSchema#string

Javed Sheikh

http://www.w3.org/2001/XMLSchema#string

Johannes Huss-Marp

http://www.w3.org/2001/XMLSchema#string

Johannes Ring

http://www.w3.org/2001/XMLSchema#string

Joseph H Butterfield

http://www.w3.org/2001/XMLSchema#string

Kristin M Leiferman

http://www.w3.org/2001/XMLSchema#string

P2860

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.

Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Lymphocytic variant hypereosinophilic syndromes.

Novel approaches to therapy of hypereosinophilic syndromes.

Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

P304

1319-25.e3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACI.2009.09.022

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Jean Emmanuel Kahn

Thomas B Nutman

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38086155

http://www.w3.org/2001/XMLSchema#string

P698

19910029

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

2829669

http://www.w3.org/2001/XMLSchema#string